Izokibep Improves Multiple PsA Symptoms in Phase 2 Study

Greater percentages of patients treated with one of two doses of the novel IL-17 blocker achieved an ACR 50 response vs placebo.

Related Keywords

Germany ,Sweden ,United States ,Frankfurt ,Brandenburg ,Frank Behrens ,Glaxosmithkline ,Pharma Advanced Research ,Amgen ,European Congress ,Boehringer Ingelheim ,American College Of Rheumatology ,Goethe University Frankfurt ,Gilead Sciences Inc ,Novartis ,Medscape Professional Network ,Fresenius ,Pfizer ,Bristol Myers Squibb ,American College ,Psoriasis Area ,Severity Index ,Immagene Biopharmaceuticals ,Two Doses ,Psoriatic Arthritis ,Leeds Enthesitis ,Psoriatic Impact ,Gilead Sciences ,Advanced Research ,Nordic Pharma ,Medscape Professional ,Psoriasis ,Clinical Research ,Clinical Trials ,Linical Studies ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Ankylosing Spondylitis Bechterews Disease ,Arthritis ,Oint Inflammation ,Biologic Therapy ,Dermatoses ,Skin Disorders ,Skin Diseases ,Monoclonal Antibody ,Etuximab ,Ituximab ,Ankylosing Spondylitis ,Europe , ,